ORAL BIVALENT TYPES 1 AND 3 POLIOMYELITIS VACCINE

Indications

• Induction of anesthesia
• Maintenance of anesthesia during surgery
• Sedation for procedures
• Pain management

Dosage

Children: Dosing in pediatric patients must be determined based on the specific agent and the child's age, weight, and clinical condition. Refer to BNF for Children for precise dosing recommendations.

Adults: Dosing varies widely based on the specific anaesthetic agent and the procedure being performed. Refer to specific guidelines or BNF for exact dosing information.

Mechanism of action

Least-acting anaesthetics primarily exert their effects by enhancing inhibitory neurotransmission, particularly through the modulation of gamma-aminobutyric acid (GABA) receptors. This results in increased chloride ion influx into neurons, leading to hyperpolarization and decreased neuronal excitability. Additionally, these agents may inhibit excitatory neurotransmitter pathways, contributing to their anesthetic effects.

Pharmacodynamics

The pharmacodynamics of least-acting anaesthetics involve a balance between sedation and analgesia, with the goal of achieving an appropriate depth of anesthesia for surgical procedures. The effects are dose-dependent, with lower doses providing sedation and higher doses leading to full anesthesia. The therapeutic window is critical, as excessive doses can lead to respiratory depression and cardiovascular instability.

Pharmacokinetics

Least-acting anaesthetics are generally characterized by rapid absorption and distribution, allowing for quick onset of action. They are metabolized primarily in the liver, with some agents undergoing hydrolysis in the plasma. The elimination half-life can vary significantly among different agents, influencing the duration of action. Factors such as age, liver function, and concurrent medications can affect the pharmacokinetics of these agents.

Pregnancy

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised; it is recommended to consult a healthcare provider before use.

Storage

Store in a cool, dry place, away from direct light and moisture.

Indications

• Moderate to severe pain management
• Chronic pain conditions
• Palliative care
• Cancer pain management

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing recommendations.

Adults: Refer to specific medical guidelines for dosing, as individual patient factors must be considered.

Mechanism of action

Levorphanol acts primarily as a mu-opioid receptor agonist, which leads to the inhibition of ascending pain pathways in the central nervous system. This action alters the perception of and response to pain. Additionally, levorphanol has some interaction with kappa and delta opioid receptors, contributing to its analgesic effects. It also inhibits the reuptake of norepinephrine and serotonin, which may enhance its pain-relieving properties.

Pharmacodynamics

The analgesic effects of levorphanol are dose-dependent and are characterized by a rapid onset of action and a relatively long duration of effect compared to other opioids. It can cause significant sedation, respiratory depression, and potential for dependence and tolerance with prolonged use. Levorphanol may also cause side effects such as constipation and nausea, typical of opioid medications.

Pharmacokinetics

Levorphanol is well-absorbed after oral administration, with a bioavailability of approximately 90%. It undergoes extensive hepatic metabolism, and its metabolites are primarily excreted via the kidneys. The half-life of levorphanol is approximately 9-12 hours, allowing for dosing every 6-12 hours depending on the clinical situation. The drug's pharmacokinetics can be influenced by factors such as liver function and concomitant medications.

Pregnancy

Consult with a healthcare provider for risk assessment as data on safety during pregnancy is limited.

Breast-feeding

Consult with a healthcare provider as it is not clear if this drug passes into breast milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Prevention of poliomyelitis infection
• Vaccination in children and high-risk populations

Dosage

Children: Refer to the BNF for Children for specific dosages and recommendations for vaccination schedules.

Adults: Refer to specific vaccination guidelines for adults, as dosages may vary based on risk factors and prior vaccination history.

Mechanism of action

Poliovirus enters the body through the oral route, replicating in the oropharynx and gastrointestinal tract before spreading to the central nervous system via the bloodstream. Once inside the CNS, the virus selectively infects motor neurons in the anterior horn of the spinal cord, leading to cell lysis and resulting in muscle weakness or paralysis. The immune response to the virus contributes to inflammation and further neuronal damage.

Pharmacodynamics

The poliovirus's pathogenicity is primarily due to its ability to evade the host's immune response and its selective neurotropism. The destruction of motor neurons leads to flaccid paralysis, with recovery possible in some cases as the motor neurons may regenerate. The severity of the disease correlates with the extent of neuronal involvement, which can vary widely among individuals.

Pharmacokinetics

Poliovirus is an RNA virus that does not undergo traditional pharmacokinetic processes as it is not treated with drugs. Instead, the prevention of polio relies on vaccination strategies. The inactivated poliovirus vaccine (IPV) and the oral poliovirus vaccine (OPV) are used to induce immunity. After administration, the vaccines promote the development of antibodies against the virus without causing disease.

Contra-indications

• Hypersensitivity to the vaccine component
• Severe immunodeficiency
• Acute febrile illness

Adverse effects

• Pain at injection site
• Fever
• Fatigue
• Headache
• Nausea
• Allergic reactions

Interactions

• Immunosuppressive therapies may reduce vaccine efficacy
• Concomitant administration with other vaccines may affect immune response

Precautions

• Use with caution in individuals with moderate to severe acute illness
• Consider history of allergic reactions
• Monitor for signs of anaphylaxis after administration

Pregnancy

Poliomyelitis vaccination is generally considered safe during pregnancy, but consult a healthcare professional.

Breast-feeding

The vaccine is considered safe for breastfeeding mothers.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Inactivated poliovirus vaccine (IPV)
• Oral poliovirus vaccine (OPV)

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.